2025 Q4 -tulosraportti
Vain PDF
107 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenCreate Medicines to the clinic: A new stress test for in vivo CAR-T BioWorld 31.07.2026: "Create Medicines Inc. has received Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human study of CRT-402, the company’s lead in vivo CAR T candidate for the treatment of autoimmune diseases." While the market is still digesting the billion-dollar waves from Big Pharma, the next milestone rolls in from the sidelines. Create Medicines has received the green light from Australian health authorities to start phase 1/2 studies in humans with CRT-402. This is the company's first program moving outside oncology, directly targeting autoimmune diseases such as lupus (SLE), systemic sclerosis, and inflammatory myopathies. Technological distinction: mRNA vs. circRNA The choice of traditional mRNA in autoimmunity is a strategic one: In cancer, a long-lasting persistent effect is often desired, but in autoimmune diseases, a controlled, transient "reset" of the immune system is wanted. Since traditional mRNA degrades quickly, it minimizes the risk of long-term and potentially dangerous immune deficiency. Create uses traditional mRNA (transient effect), Sail uses synthetic circRNA (longer duration), while Circio ($CRCI) delivers DNA-based circVec. In short: Create delivers the RNA payload. Circio delivers the factory recipe for long-term production. The regulatory snowplow That the approval comes from HREC in Australia is no coincidence; Australia is known for a faster and more predictable approval process than the American FDA, which allows smaller companies to reach the clinic much faster and cheaper. Every time regulatory authorities approve the testing of a new in vivo CAR-T platform in humans, the regulatory risk for the entire field is reduced. That authorities are now becoming comfortable with approving systemically administered lipid nanoparticles (LNPs) for direct genetic programming of immune cells, removes a significant barrier for all who follow. The first clinical thermometer Create can now become one of the first real clinical thermometers for the entire in vivo CAR-T segment. CRT-402 is a CD19-targeted candidate against autoimmune diseases, and the company states that preclinical studies showed sustained B-cell depletion. Now these results will be tested in humans. This makes the study interesting far beyond Create itself. Firstly, it will provide valuable data on how well LNPs are tolerated in the clinic. Secondly, it will test the therapeutic dogma itself: Can immune cells actually be reprogrammed directly in the body to achieve deep B-cell depletion without unacceptable side effects? If CRT-402 shows a good safety profile and clear biological effect, it will likely provide tailwind to the entire in vivo CAR-T segment. Should the study encounter problems, it will broadly affect sentiment. Conclusion Just days after J&J signaled its belief in in vivo CAR-T through the billion-dollar deal with Sail, we now see another player stepping into the clinic. This is not a direct validation of circVec or Circio. But it is yet another proof that the field is moving rapidly from theoretical discussions to actual studies in humans. Create Medicines will be one of the first true thermometers for in vivo CAR-T in the clinic. For investors in RNA and cell therapy, the data from here will be the definitive starting gun – or a reality check – for the next generation of medicine.Eli Lilly brings in vivo CAR-T to Norway: Rolls out study in Oslo "During the autumn, the pharmaceutical company Lilly will start clinical trials on a revolutionary form of cell therapy. Oslo myelomatosesenter will participate in the study." (Dagens Medisin, 15.07.2026) While autoimmunity has stolen the headlines, in vivo CAR-T is now rapidly moving into cancer treatment – all the way to Norway. This autumn, Oslo myelomatosesenter and chief physician Fredrik Schjesvold will start clinical trials with Eli Lilly's leading in vivo candidate (KLN-1010) against bone marrow cancer. Breaking the logistical bottlenecks The treatment eliminates the traditional demanding logistics of cell harvesting (apheresis), weeks of lab production, and tough chemotherapy regimens. Instead, the therapy is injected directly intravenously as an "off-the-shelf" solution that reprograms T-cells directly in the body. Cancer vs. autoimmunity This underscores an important distinction in the field: Autoimmunity (e.g., Create): Often uses transient mRNA for a controlled "reset" of the immune system. Cancer (Lilly): The goal is often deep and sustained response, which historically has favored solutions that achieve long-lasting cell activity. What does this mean for Circio ($CRCI)? That Big Pharma is now rolling out in vivo CAR-T in clinical trials at Norwegian hospitals has two clear effects for $CRCI: Market validation: It confirms that oncology remains one of the most important drivers for next-generation cell therapy and direct immune cell programming. Strategic pressure: When giants like Lilly establish themselves broadly in the clinic, competition increases to identify and secure the platforms that can deliver the most effective and lasting cell programming. The field is long out of the laboratory. Now it is being tested on patients.
·4 t sittenHigh turnover today, 52.3 million is not bad now during the holiday. This will be good in the long run.
·5 t sittenSomeone sold and bought a position of 530.000 shares 😮
Well, algos have it. Everything is about dynamics and excitement. It creates "space" and dynamics for itself.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
107 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenCreate Medicines to the clinic: A new stress test for in vivo CAR-T BioWorld 31.07.2026: "Create Medicines Inc. has received Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human study of CRT-402, the company’s lead in vivo CAR T candidate for the treatment of autoimmune diseases." While the market is still digesting the billion-dollar waves from Big Pharma, the next milestone rolls in from the sidelines. Create Medicines has received the green light from Australian health authorities to start phase 1/2 studies in humans with CRT-402. This is the company's first program moving outside oncology, directly targeting autoimmune diseases such as lupus (SLE), systemic sclerosis, and inflammatory myopathies. Technological distinction: mRNA vs. circRNA The choice of traditional mRNA in autoimmunity is a strategic one: In cancer, a long-lasting persistent effect is often desired, but in autoimmune diseases, a controlled, transient "reset" of the immune system is wanted. Since traditional mRNA degrades quickly, it minimizes the risk of long-term and potentially dangerous immune deficiency. Create uses traditional mRNA (transient effect), Sail uses synthetic circRNA (longer duration), while Circio ($CRCI) delivers DNA-based circVec. In short: Create delivers the RNA payload. Circio delivers the factory recipe for long-term production. The regulatory snowplow That the approval comes from HREC in Australia is no coincidence; Australia is known for a faster and more predictable approval process than the American FDA, which allows smaller companies to reach the clinic much faster and cheaper. Every time regulatory authorities approve the testing of a new in vivo CAR-T platform in humans, the regulatory risk for the entire field is reduced. That authorities are now becoming comfortable with approving systemically administered lipid nanoparticles (LNPs) for direct genetic programming of immune cells, removes a significant barrier for all who follow. The first clinical thermometer Create can now become one of the first real clinical thermometers for the entire in vivo CAR-T segment. CRT-402 is a CD19-targeted candidate against autoimmune diseases, and the company states that preclinical studies showed sustained B-cell depletion. Now these results will be tested in humans. This makes the study interesting far beyond Create itself. Firstly, it will provide valuable data on how well LNPs are tolerated in the clinic. Secondly, it will test the therapeutic dogma itself: Can immune cells actually be reprogrammed directly in the body to achieve deep B-cell depletion without unacceptable side effects? If CRT-402 shows a good safety profile and clear biological effect, it will likely provide tailwind to the entire in vivo CAR-T segment. Should the study encounter problems, it will broadly affect sentiment. Conclusion Just days after J&J signaled its belief in in vivo CAR-T through the billion-dollar deal with Sail, we now see another player stepping into the clinic. This is not a direct validation of circVec or Circio. But it is yet another proof that the field is moving rapidly from theoretical discussions to actual studies in humans. Create Medicines will be one of the first true thermometers for in vivo CAR-T in the clinic. For investors in RNA and cell therapy, the data from here will be the definitive starting gun – or a reality check – for the next generation of medicine.Eli Lilly brings in vivo CAR-T to Norway: Rolls out study in Oslo "During the autumn, the pharmaceutical company Lilly will start clinical trials on a revolutionary form of cell therapy. Oslo myelomatosesenter will participate in the study." (Dagens Medisin, 15.07.2026) While autoimmunity has stolen the headlines, in vivo CAR-T is now rapidly moving into cancer treatment – all the way to Norway. This autumn, Oslo myelomatosesenter and chief physician Fredrik Schjesvold will start clinical trials with Eli Lilly's leading in vivo candidate (KLN-1010) against bone marrow cancer. Breaking the logistical bottlenecks The treatment eliminates the traditional demanding logistics of cell harvesting (apheresis), weeks of lab production, and tough chemotherapy regimens. Instead, the therapy is injected directly intravenously as an "off-the-shelf" solution that reprograms T-cells directly in the body. Cancer vs. autoimmunity This underscores an important distinction in the field: Autoimmunity (e.g., Create): Often uses transient mRNA for a controlled "reset" of the immune system. Cancer (Lilly): The goal is often deep and sustained response, which historically has favored solutions that achieve long-lasting cell activity. What does this mean for Circio ($CRCI)? That Big Pharma is now rolling out in vivo CAR-T in clinical trials at Norwegian hospitals has two clear effects for $CRCI: Market validation: It confirms that oncology remains one of the most important drivers for next-generation cell therapy and direct immune cell programming. Strategic pressure: When giants like Lilly establish themselves broadly in the clinic, competition increases to identify and secure the platforms that can deliver the most effective and lasting cell programming. The field is long out of the laboratory. Now it is being tested on patients.
- ·4 t sittenHigh turnover today, 52.3 million is not bad now during the holiday. This will be good in the long run.
- ·5 t sittenSomeone sold and bought a position of 530.000 shares 😮Well, algos have it. Everything is about dynamics and excitement. It creates "space" and dynamics for itself.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
107 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenCreate Medicines to the clinic: A new stress test for in vivo CAR-T BioWorld 31.07.2026: "Create Medicines Inc. has received Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human study of CRT-402, the company’s lead in vivo CAR T candidate for the treatment of autoimmune diseases." While the market is still digesting the billion-dollar waves from Big Pharma, the next milestone rolls in from the sidelines. Create Medicines has received the green light from Australian health authorities to start phase 1/2 studies in humans with CRT-402. This is the company's first program moving outside oncology, directly targeting autoimmune diseases such as lupus (SLE), systemic sclerosis, and inflammatory myopathies. Technological distinction: mRNA vs. circRNA The choice of traditional mRNA in autoimmunity is a strategic one: In cancer, a long-lasting persistent effect is often desired, but in autoimmune diseases, a controlled, transient "reset" of the immune system is wanted. Since traditional mRNA degrades quickly, it minimizes the risk of long-term and potentially dangerous immune deficiency. Create uses traditional mRNA (transient effect), Sail uses synthetic circRNA (longer duration), while Circio ($CRCI) delivers DNA-based circVec. In short: Create delivers the RNA payload. Circio delivers the factory recipe for long-term production. The regulatory snowplow That the approval comes from HREC in Australia is no coincidence; Australia is known for a faster and more predictable approval process than the American FDA, which allows smaller companies to reach the clinic much faster and cheaper. Every time regulatory authorities approve the testing of a new in vivo CAR-T platform in humans, the regulatory risk for the entire field is reduced. That authorities are now becoming comfortable with approving systemically administered lipid nanoparticles (LNPs) for direct genetic programming of immune cells, removes a significant barrier for all who follow. The first clinical thermometer Create can now become one of the first real clinical thermometers for the entire in vivo CAR-T segment. CRT-402 is a CD19-targeted candidate against autoimmune diseases, and the company states that preclinical studies showed sustained B-cell depletion. Now these results will be tested in humans. This makes the study interesting far beyond Create itself. Firstly, it will provide valuable data on how well LNPs are tolerated in the clinic. Secondly, it will test the therapeutic dogma itself: Can immune cells actually be reprogrammed directly in the body to achieve deep B-cell depletion without unacceptable side effects? If CRT-402 shows a good safety profile and clear biological effect, it will likely provide tailwind to the entire in vivo CAR-T segment. Should the study encounter problems, it will broadly affect sentiment. Conclusion Just days after J&J signaled its belief in in vivo CAR-T through the billion-dollar deal with Sail, we now see another player stepping into the clinic. This is not a direct validation of circVec or Circio. But it is yet another proof that the field is moving rapidly from theoretical discussions to actual studies in humans. Create Medicines will be one of the first true thermometers for in vivo CAR-T in the clinic. For investors in RNA and cell therapy, the data from here will be the definitive starting gun – or a reality check – for the next generation of medicine.Eli Lilly brings in vivo CAR-T to Norway: Rolls out study in Oslo "During the autumn, the pharmaceutical company Lilly will start clinical trials on a revolutionary form of cell therapy. Oslo myelomatosesenter will participate in the study." (Dagens Medisin, 15.07.2026) While autoimmunity has stolen the headlines, in vivo CAR-T is now rapidly moving into cancer treatment – all the way to Norway. This autumn, Oslo myelomatosesenter and chief physician Fredrik Schjesvold will start clinical trials with Eli Lilly's leading in vivo candidate (KLN-1010) against bone marrow cancer. Breaking the logistical bottlenecks The treatment eliminates the traditional demanding logistics of cell harvesting (apheresis), weeks of lab production, and tough chemotherapy regimens. Instead, the therapy is injected directly intravenously as an "off-the-shelf" solution that reprograms T-cells directly in the body. Cancer vs. autoimmunity This underscores an important distinction in the field: Autoimmunity (e.g., Create): Often uses transient mRNA for a controlled "reset" of the immune system. Cancer (Lilly): The goal is often deep and sustained response, which historically has favored solutions that achieve long-lasting cell activity. What does this mean for Circio ($CRCI)? That Big Pharma is now rolling out in vivo CAR-T in clinical trials at Norwegian hospitals has two clear effects for $CRCI: Market validation: It confirms that oncology remains one of the most important drivers for next-generation cell therapy and direct immune cell programming. Strategic pressure: When giants like Lilly establish themselves broadly in the clinic, competition increases to identify and secure the platforms that can deliver the most effective and lasting cell programming. The field is long out of the laboratory. Now it is being tested on patients.
- ·4 t sittenHigh turnover today, 52.3 million is not bad now during the holiday. This will be good in the long run.
- ·5 t sittenSomeone sold and bought a position of 530.000 shares 😮Well, algos have it. Everything is about dynamics and excitement. It creates "space" and dynamics for itself.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt